Literature DB >> 2554580

Persistence of varicella-zoster virus DNA in blood mononuclear cells of patients with varicella or zoster.

D H Gilden1, M Devlin, M Wellish, R Mahalingham, C Huff, A Hayward, A Vafai.   

Abstract

Varicella-zoster virus (VZV) DNA was detectable by in-situ hybridization in blood mononuclear cells (MNCs) of patients with varicella or zoster for 2-56 days after the onset of a rash. VZV DNA was present in many MNCs from one acute varicella patient 2 days after the onset of the rash and was rarely found in MNCs during acute zoster, convalescent zoster, and convalescent varicella. The morphology of MNCs containing VZV was heterogenous, although most viral-DNA-containing MNCs were large monocytoid cells. Serial examination of blood MNCs from one adult with varicella revealed VZV DNA up until 8 weeks, but not 16 weeks, after the appearance of the rash; parallel studies in four zoster patients showed VZV DNA up until 3 weeks, but not later than 7 weeks after the appearance of the rash. These results indicate that MNCs become infected with VZV during the primary encounter with VZV (varicella) and during reactivation (zoster) and that infection continues for weeks after the onset of the skin rash. Furthermore, the detection of VZV DNA in blood MNCs of uncomplicated zoster patients coincides with the period during which these patients experience pain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554580     DOI: 10.1007/BF00684037

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  13 in total

1.  Viremia caused by varicella-zoster virus: association with malignant progressive varicella.

Authors:  M G Myers
Journal:  J Infect Dis       Date:  1979-08       Impact factor: 5.226

2.  Detection of varicella-zoster virus nucleic acid in neurons of normal human thoracic ganglia.

Authors:  D H Gilden; Y Rozenman; R Murray; M Devlin; A Vafai
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

3.  Varicella-zoster virus infection of human brain cells and ganglion cells in tissue culture.

Authors:  D H Gilden; Z Wroblewska; V Kindt; K G Warren; J S Wolinsky
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

4.  Varicella-zoster viremia.

Authors:  A A Gershon; S Steinberg; R Silber
Journal:  J Pediatr       Date:  1978-06       Impact factor: 4.406

5.  Viremic phase in nonimmunocompromised children with varicella.

Authors:  T Ozaki; T Ichikawa; Y Matsui; T Nagai; Y Asano; K Yamanishi; M Takahashi
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

6.  Varicella-zoster virus infection of human mononuclear cells.

Authors:  D H Gilden; A R Hayward; J Krupp; M Hunter-Laszlo; J C Huff; A Vafai
Journal:  Virus Res       Date:  1987-04       Impact factor: 3.303

7.  Evolutionary comparisons of the S segments in the genomes of herpes simplex virus type 1 and varicella-zoster virus.

Authors:  A J Davison; D J McGeoch
Journal:  J Gen Virol       Date:  1986-04       Impact factor: 3.891

8.  Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies.

Authors:  A Vafai; Z Wroblewska; R Mahalingam; G Cabirac; M Wellish; M Cisco; D Gilden
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Chronic progressive varicella-zoster virus encephalitis in an AIDS patient.

Authors:  D H Gilden; R S Murray; M Wellish; B K Kleinschmidt-DeMasters; A Vafai
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910

10.  Expression of varicella-zoster virus in blood mononuclear cells of patients with postherpetic neuralgia.

Authors:  A Vafai; M Wellish; D H Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

View more
  6 in total

1.  Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence.

Authors:  M D de Jong; J F Weel; T Schuurman; P M Wertheim-van Dillen; R Boom
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Persistence of varicella zoster virus DNA in saliva after herpes zoster.

Authors:  Maria A Nagel; Alexander Choe; Randall J Cohrs; Igor Traktinskiy; Kyle Sorensen; Satish K Mehta; Duane L Pierson; Stephen K Tyring; Kassie Haitz; Catherine Digiorgio; Whitney Lapolla; Don Gilden
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

3.  Chronic varicella-zoster virus ganglionitis--a possible cause of postherpetic neuralgia.

Authors:  Donald H Gilden; Randall J Cohrs; Anthony R Hayward; Mary Wellish; Ravi Mahalingam
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 4.  The cancer patient with chronic pain due to herpes zoster.

Authors:  S Modi; J Pereira; J R Mackey
Journal:  Curr Rev Pain       Date:  2000

Review 5.  Postherpetic neuralgia in the cancer patient.

Authors:  E Lojeski; R A Stevens
Journal:  Curr Rev Pain       Date:  2000

Review 6.  Manipulation of the Innate Immune Response by Varicella Zoster Virus.

Authors:  Chelsea Gerada; Tessa M Campbell; Jarrod J Kennedy; Brian P McSharry; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.